Imaging cancer using single photon techniques.

Area of Science:

• Nuclear oncology
• Medical imaging
• Radiochemistry

Background:

• Positron emission tomography (PET) is a leading nuclear oncology imaging modality.
• Single photon tracers, like thallium-201 (Tl) and somatostatin analogues, are vital for visualizing many cancers.
• Understanding cancer biology and exploiting differences between cancerous and normal tissues are key for diagnosis.

Purpose of the Study:

• To review the scope of single photon tracers in oncology.
• To highlight the continued importance of SPECT imaging alongside PET.
• To discuss advancements in SPECT technology and new tracer development for cancer management.

Main Methods:

• Review of current literature on single photon tracer applications in oncology.
• Discussion of emerging receptor systems (gastrin, bombesin) and targeted agents (e.g., for hypoxia, angiogenesis, apoptosis).
• Emphasis on the integration of SPECT/CT systems for improved image co-registration and diagnostic accuracy.

Main Results:

• Single photon imaging remains essential for cancer diagnosis and treatment assessment, often at a lower cost than PET.
• New SPECT agents can identify key cancer processes like hypoxia, angiogenesis, and apoptosis.
• Dual-modality SPECT/CT systems significantly improve lesion localization and diagnostic confidence by fusing functional and anatomical data.

Conclusions:

• Single photon imaging, particularly with SPECT/CT, offers valuable, cost-effective solutions in nuclear oncology.
• Advancements in tracers and imaging technology continue to expand the role of SPECT in cancer diagnosis and management.
• High-quality SPECT imaging is increasingly important for preassessment in radionuclide therapy and overall clinical decision-making.